Comparative Pharmacology
Head-to-head clinical analysis: GLUCOTROL versus GLUCOTROL XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOTROL versus GLUCOTROL XL.
GLUCOTROL vs GLUCOTROL XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor 1 (SUR1) on ATP-sensitive potassium channels, causing depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Stimulates insulin secretion from pancreatic beta cells by binding to ATP-sensitive potassium channels, causing depolarization and calcium influx, leading to insulin release.
Initial dose 5 mg orally once daily, increased by 2.5-5 mg increments weekly based on glycemic response; maximum 20 mg daily as single or divided doses (for doses >15 mg, administer in divided doses).
Initial dose: 5 mg orally once daily with breakfast. Titrate by 2.5-5 mg increments at weekly intervals based on glycemic response. Maximum dose: 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (mean 3.4 hours) in normal subjects; extended up to 8-12 hours in elderly or hepatic impairment due to reduced clearance.
Terminal elimination half-life 2-5 hours; however, due to extended-release formulation, therapeutic effects persist up to 24 hours.
Primarily renal: ~80% as metabolites (mainly 4-trans-hydroxyglipizide and 3-cis-hydroxyglipizide) and ~10% unchanged; fecal: ~10%.
Renal: ~70% as metabolites (primarily hydroxylated and conjugated metabolites), unchanged drug <10%; Fecal: ~20% via bile.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic